Ipsen and Braintree Laboratories have signed an agreement for the exclusive manufacturing, marketing and distribution rights of the latter’s proprietary formulation – BLI-800, in colonic cleansing before colonoscopy for colorectal cancer screening.
Subject to obtaining marketing approvals, BLI-800 will allow colonic cleansing with reduced volumes of liquid ingested compared to some existing drugs, including Ipsen’s currently marketed Fortrans.
Reportedly, the agreement covers countries within the EU, Commonwealth of Independent States, selected Asian countries (including China) and some North African countries.
Under the agreement, Braintree will receive payments upon achievement of certain milestones such as product launches and commercial thresholds. Additionally, Braintree will receive royalties on Ipsen’s sales.
Stephane Thiroloix, executive vice-president of corporate development at Ipsen, said: “The agreement with Braintree over BLI-800 will further contribute to the implementation of our Primary Care strategy by complementing Ipsen’s gastro-enterology portfolio.Once approved, BLI-800 will provide physicians and patients with a valuable agent for pre-colonoscopy colonic cleansing, particularly in the screening of colorectal cancer.”
Harry Keegan III, CEO of Braintree, said: “We are very confident in the far-reaching and accomplished development, marketing and distribution networks that Ipsen has established across the territories involved in this agreement.”